How Far Is Too Far? The Ethics of Mini Brain Research
December 11, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
cibinqo
Synonyms :
abrocitinib
Class :
Dermatologicals, Janus kinase inhibitors
Brand Name :
cibinqo
Synonyms :
abrocitinib
Class :
Dermatologicals, Janus kinase inhibitors
Dosage Forms & Strengths
Tablet
50mg
100mg
200mg
100
mg
Tablet
Orally
every day initially
can increase up to 200mg
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
corticosteroids may enhance the immunosuppressive effect of abrocitinib
corticosteroids may enhance the immunosuppressive effect of abrocitinib
corticosteroids may enhance the immunosuppressive effect of abrocitinib
corticosteroids may enhance the immunosuppressive effect of abrocitinib
corticosteroids may enhance the immunosuppressive effect of abrocitinib
may increase the antiplatelet effect
may enhance the serum concentration of P-glycoprotein inhibitors
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may decrease the therapeutic effect
may increase the neutropenic effect
may increase the immunosuppressive effect
may enhance the serum concentration of P-glycoprotein inhibitors
may decrease the therapeutic effect
may enhance the serum concentration of P-glycoprotein inhibitors
may enhance the serum concentration of P-glycoprotein inhibitors
measles, mumps, rubella, and varicella vaccine, live (Rx)
may increase the toxic effect of immunosuppressants
measles mumps and rubella vaccine, live
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
vaccinia immune globulin intravenous (Rx)
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
may reduce the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may reduce the therapeutic effect of vaccines
poliovirus vaccine inactivated
may reduce the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may reduce the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may have an increased immunosuppressive effect when combined with abrocitinib
may have an increased immunosuppressive effect when combined with abrocitinib
may have an increased immunosuppressive effect when combined with abrocitinib
may have an increased immunosuppressive effect when combined with abrocitinib
may have an increased immunosuppressive effect when combined with abrocitinib
may decrease the therapeutic effect when combined with COVID-19 vaccine
respiratory syncytial virus vaccine, adjuvanted
may have a decreased therapeutic effect of influenza virus vaccines
respiratory syncytial virus (RSV) vaccine
may have a decreased therapeutic effect of influenza virus vaccines
abrocitinib: it may enhance the toxic effect of Anti-Inflammatory Agents
abrocitinib: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
abrocitinib: it may enhance the toxic effect of Anti-Inflammatory Agents
abrocitinib: it may enhance the toxic effect of Anti-Inflammatory Agents
abrocitinib: it may enhance the toxic effect of Anti-Inflammatory Agents
may diminish the therapeutic effect of drug
immunosuppressants may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the diagnostic effect when combined with coccidioides immitis skin test
may have an increased immunosuppressive effect when combined with denosumab
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of immunosuppressants
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
smallpox (vaccinia) vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may have an increased antiplatelet effect when combined with abrocitinib
may have an increased immunosuppressive effect when combined with leflunomide
may decrease the therapeutic effect when combined with sipuleucel-t
may increase the immunosuppressive effect of Immunosuppressants
may decrease the therapeutic effect when combined with covid-19 vaccine
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine, h5n1, live
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine (h5n1), adjuvanted
may decrease the therapeutic effect when combined with influenza virus vaccines
may diminish the metabolism of each other when combined
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
antiplatelet agents increase the antiplatelet effect of abrocitinib
antiplatelet agents increase the antiplatelet effect of abrocitinib
antiplatelet agents increase the antiplatelet effect of abrocitinib
antiplatelet agents increase the antiplatelet effect of abrocitinib
antiplatelet agents increase the antiplatelet effect of abrocitinib
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the immunosuppressive effect
may decrease the therapeutic effect
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may enhance the serum concentration
may enhance the serum concentration
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with Abrocitinib
may have an increased antiplatelet effect when combined with Abrocitinib
may have an increased antiplatelet effect when combined with Abrocitinib
may have an increased antiplatelet effect when combined with Abrocitinib
may have an increased antiplatelet effect when combined with Abrocitinib
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
measles, mumps, rubella, and varicella vaccine, live
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
May increase the immunosuppressive effect of abrocitinib
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may increase excessive immunosuppressive effects and risk of infection
may increase excessive immunosuppressive effects and risk of infection
may increase excessive immunosuppressive effects and risk of infection
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of abrocitinib
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in the effect of immunosuppressants
when both drugs are combined, there may be increase in the effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
it may increase the immunosuppressive effect of immunosuppressants
antiplatelet agents increase the effect of abrocitinib
may increase the immunosuppressive effects
may increase the toxic effect of anti-platelet agents
may enhance the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressive agents
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may enhance the adverse/toxic effect
poliovirus vaccine, live, trivalent
may enhance the adverse/toxic effect
poliovirus vaccine inactivated
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with talimogene laherparepvec
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increasingly adverse effect when combined with BCG products
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
cladribine: they may increase the immunosuppressive effect of selective immunosuppressants
filgrastim: they may increase the immunosuppressive effect of selective immunosuppressants
nadofaragene firadenovec: they may increase the immunosuppressive effect of selective immunosuppressants
natalizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ritlecitinib: they may increase the immunosuppressive effect of selective immunosuppressants
tacrolimus: they may increase the immunosuppressive effect of selective immunosuppressants
upadacitinib: they may increase the immunosuppressive effect of selective immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may have an increased adverse/toxic effect when combined with immunosuppressants
respiratory syncytial virus (RSV) vaccine
may have an increased adverse/toxic effect when combined with immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may diminish the pharmacodynamic antagonistic effect of each other when combined
respiratory syncytial virus (RSV) vaccine
may diminish the pharmacodynamic antagonistic effect of each other when combined
dengue vaccine efficacy will be reduced by abrocitinib
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
it may enhance the immunosuppressive effect of immunosuppressants
it may enhance the immunosuppressive effect of immunosuppressants
it may enhance the immunosuppressive effect of immunosuppressants
it may enhance the immunosuppressive effect of immunosuppressants
it may enhance the immunosuppressive effect of immunosuppressants
may increase the myelosuppressive effect
may increase the myelosuppressive effect
may enhance the serum concentration of P-glycoprotein inhibitors
may enhance the serum concentration
may decrease the therapeutic effect
may increase the toxic effect of myelosuppressive effect
may enhance the serum concentration
may increase the toxic effect of the myelosuppressive effect
may enhance the serum concentration
may decrease the serum concentration
may enhance the serum concentration
respiratory syncytial virus vaccine, adjuvanted
may diminish the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may diminish the therapeutic effect of vaccines
it may diminish the metabolism when combined with azelastine
when netupitant is combined with abrocitinib, it can lead to a reduced metabolism of abrocitinib
The combination of mibefradil and abrocitinib can lead to an increase in the concentration serum of mibefradil
antipyrine with abrocitinib could potentially lead to a reduce in the metabolism of abrocitinib.
ximelagatran (investigational)
The combination of abrocitinib may lead to a reduced metabolism of ximelagatran
Combining abrocitinib with pranlukast may cause a reduction in the abrocitinib’s metabolism
It may enhance the risk of bleeding when combined with nimesulide
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
When abrocitinib is used together with fluconazole, this leads to reduction in the abrocitinib metabolism
When abrocitinib is used together with elbasvir, this leads to a rise in the concentration serum of elbasvir
When abrocitinib is used together with promazine, this leads to a reduction in abrocitinib metabolism
may diminish the immunosuppressive effect of each other when combined
measles, mumps, rubella, and varicella vaccine, live
may diminish the immunosuppressive effect of each other when combined
measles mumps and rubella vaccine, live
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
smallpox (vaccinia) vaccine, live
may diminish the immunosuppressive effect of each other when combined
combining buflomedil with abrocitinib may increase the incidence or severity of bleeding and thrombocytopenia
When indisulam is used together with abrocitinib, this leads to a reduction in abrocitinib metabolism
abrocitinib: it may decrease the metabolism of lornoxicam
the risk of bleeding and thrombocytopenia can be raised when sulfinpyrazone is combined with abrocitinib
abrocitinib: it may increase the risk of bleeding and thrombocytopenia with indobufen
may enhance the risk of serious infection by increasing immunosuppressive effect of methotrexate
interaction may raise the risk of serious infections due to immunosuppressive effects
may increase excessive immunosuppressive effects
may decrease the therapeutic effect when combined with pneumococcal vaccines
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with brincidofovir
may increase the immunosuppressive effect of immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
inebilizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ocrelizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ofatumumab: they may increase the immunosuppressive effect of selective immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
when coupled with asunaprevir, abrocitinib's metabolism may be slowed down
the rate of metabolism of abrocitinib is reduced
the efficacy of the vaccine may be reduced
the serum concentration of abrocitinib can be elevated when combined with ivacaftor
the rate of metabolism of abrocitinib may be reduced
the serum levels of cethromycin may be increased
the rate of metabolism of atrocities may be decreased
the rate of metabolism of abrocitinib may be reduced
the rate of metabolism of abrocitinib may be reduced
the risk of bleeding may be increased
when both drugs are combined, there may be a decrease in the therapeutic effect
When abrocitinib is used together with vonoprazan, this leads to reduction in abrocitinib’s metabolism
Frequency defined:
>10%
Nasopharyngitis
Nausea
1-10%
Acne
Vomiting
Dizziness
Upper abdominal pain
Impetigo
Oropharyngeal pain
Influenza
Abdominal pain
Contact dermatitis
Headache
Herpes simplex
Urinary tract infection
Fatigue
Thrombocytopenia
Gastroenteritis
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: abrocitinib
Pronounced: [ A-broe-SYE-ti-nib]
Why do we use abrocitinib?
It is used to treat atopic dermatitis(eczema)
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
